Pegpleranib Uses, Dosage, Side Effects and more
| Trade Name | Pegpleranib |
| Generic | Pegpleranib |
| Pegpleranib Other Names | Pegpleranib |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in macular degeneration and eye disorders/infections.
How Pegpleranib works
E10030 is an aptamer based, anti-platelet-derived growth factor (PDGF) which inhibits PDGF-B with high specificity and affinity. E10030 may be efficacious in treating neovascular age-related macular degeneration when combined with a vascular endothelial growth factor A (VEGF-A) inhibitor. PDGF-B is implicated in vascular stability and function through its role in activating the recruitment of mural cells (pericytes) by endothelial cells to envelop the developing vasculature. Pericyte recruitment is part of the maturation process in blood vessel development and pericytes act as support cells for mature blood vessels. [Opthotech Corp. Website] Neovascular age-related macular degeneration is a condition where new, extremely fragile blood vessels under the retina where they burst and cause damage to surrounding tissue, resulting in vision problems.
